Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2

Cancer

Volumn 80, Issue 7, 1997, Pages 1198-1220

  Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Interferon ; Interleukin 2; Metastatic; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

BLOOD TOXICITY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; RECOMBINANT PROTEINS;

EID: 0030931682     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H     Document Type: Review

References (223)

1. American Cancer Society, Inc. Cancer Facts & Figures - 1996. Atlanta: American Cancer Society, 1996.
2. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics: 1994. CA Cancer J Clin 1994;44:7-26.
3. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma-review article. N Engl J Med 1996;12:865-75.
4. Linehan WM, Shipley W, Parkinson D. Cancer of the kidney and ureter. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: J.B. Lippincott Co, 1993:1023-51.
5. Robbins SL, Cotran RS. Pathologic basis of disease. 2nd edition. Philadelphia: W.B. Saunders Company, 1979.
6. Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for RCC. J Natl Cancer Inst 1986; 77:351-6.
7. La Vecchia C, Negri E, D'Avanzo B, Franceschi S. Smoking and RCC. Cancer Res 1990;50:5231-3.
8. McLaughlin JK, Lindblad P, Mellemgaard A, McCredie M, Mandel JS, Schlehofer B, et al. International renal-cell cancer study. I. Tobacco use. Int J Cancer 1995;60:194-8.
9. Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore) 1990;69:217-26.
10. Brennan JF, Stilmant MM, Babayan RK, Siroky MB. Acquired renal cystic disease: implications for the urologist. Br J Urol 1991;67:342-8.
11. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986;136:376-9.
12. Bertoni F, Ferri C, Benati A, Bacchini P, Corrado F. Sarcomatoid carcinoma of the kidney. J Urol 1987;137:25-8.
13. Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA. Sarcomatoid RCC: a clinicopathologic study of 42 cases. Cancer 1987;59:516-26.
14. Selli C, Hinshaw WM, Woodard BH, Paulson DF. Stratification of risk factors in RCC. Cancer 1983;52:899-903.
15. Sella A, Logothetis J, Ro JY, Swanson DA, Samuels ML. Sarcomatoid RCC: a treatable entity. Cancer 1987;60:1313-8.
16. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene: its role in renal cancer. JAMA 1995;273:564-70.
17. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R, et al. Von Hippel-Lindau disease: a genetic study. J Med Genet 1991;28:443-7.
18. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with RCC. Nature 1988;332:268-9.
19. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutation of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
20. Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garrett KP, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995;269:1402-6.
21. Kibel A, Iliopoulous O, DeCaprio JA, Kaelin WG. Binding of the von Hippel-Landau tumor suppressor protein to Elongin B & C. Science 1995;269:1444-6.
22. Kovacs G, Ishikawa I. High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 1993;22:135-9.
23. Bard RH, Lord B, Fromowitz F. Papillary adenocarcinoma of kidney. Urology 1982;19:16-20.
24. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for RCC. J Urol 1969;101:297-301.
25. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P. RCC: survival and prognostic factors. Urology 1986; 27:291-301.
26. Tsukamoto T, Kumamoto Y, Yamazaki K, Miyao N, Takahashi A, Masumori N, et al. Clinical analysis of incidentally found RCCs. Eur Urol 1991;19:109-13.
27. Haas GP, Hillman GG, Redman BG, Pontes JE. Immunotherapy of RCC. CA Cancer J Clin 1993;43:177-87.
28. Finke JH, Tubbs R, Connelly B, Pontes E, Montie J. Tumor-infiltrating lymphocytes in patients with RCC. Ann N Y Acad Sci 1988;532:387-94.
29. Bernhard H, Karbach J, Wölfel T, Busch P, Storkel S, Stockle M, et al. Cellular immune response to human renal-cell carcinoma: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Int J Cancer 1994;59:837-42.
30. Broder S, Waldmann TA. The suppressor-cell network in cancer. N Engl J Med 1978;299:1281-4.
31. Miescher S, Whitesides TL, Carrel C, Von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 1986;136:1899-907.
32. lck in T-cells infiltrating human RCC. Cancer Res 1993;53:5613-6.
33. Li X, Liu J, Park JK, Hamilton TA, Rayman P, Klein E, et al. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res 1994;54:5424-9.
34. Wang Q, Redovan C, Tubbs R, Olencki T, Klein E, Kudoh S, et al. Selective cytokine gene expression in RCC tumor cells and tumor infiltrating lymphocytes. Int J Cancer 1995;61:1-6.
35. Sokoloff MH, deKernion JB, Figlin RA, Belldegrun A. Current management of renal cell carcinoma. CA Cancer J Clin 1996; 46:284-302.
36. Sella A, Swanson DA, Ro JY, Putnam JB, Amato RJ, Markowitz AB, et al. Surgery following response to interferon-alfa-based therapy for residual RCC. J Urol 1993;149:19-22.
37. Sella A, Swanson D, Amato R, Putnam J, Ro J, Ellerhorst J, et al. Evidence for a favorable effect of surgical resection of residual metastatic RCC following biological therapy (BT) [abstract]. Proc Am Soc Clin Oncol 1993;12:246.
38. Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D. The impact of adjuvant nephrectomy on multimodality treatment of metastatic RCC. J Urol 1994;152:1399-403.
39. Novick AC. Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma. Semin Oncol 1995; 22:29-33.
40. Tolia BM, Whitmore WF. Solitary metastatis from RCC. J Urol 1975;114:836-8.
41. Rafla S. RCC: natural history and results of treatment. Cancer 1970;25:26-40.
42. O'Dea MJ, Zincke H, Utz DC, Bernatz PE. The treatment of RCC with solitary metastasis. J Urol 1978;120:540-2.
43. Halperin EC, Harisiadis L. The role of radiation therapy in the management of metastatic RCC. Cancer 1983;51:614-7.
44. Onufrey V, Mohiuddin M. Radiation therapy in the treatment of metastatic RCC. Int J Radiat Oncol Biol Phys 1985; 11:2007-9.
45. Harris DT. Hormonal therapy and chemotherapy of RCC. Semin Oncol 1983;10:422-30.
46. Yagoda A, Bander NH. Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 1989;44:338-45.
47. Yagoda A. Phase II cytotoxic chemotherapy trials in RCC: 1983-1988. Prog CKn Biol Res 1990;350:227-41.
48. Warner E, Tobe S, Pei Y, Trachtenberg J, Skorecki K. Phase I trial of vinblastine (VBL) with oral cyclosporine A (CSA) as a multidrug resistance modifier in RCC [abstract]. Proc Am Soc Clin Oncol 1992;11:204.
49. Lemon S, Meadows B, Fojo A, Goldspiel B, Bates S. A phase I study of infusional vinblastine with the p-glycoprotein antogonist PSC 833 in patients with metastatic cancer [abstract]. Proc Am Soc Clin Oncol 1995;14:479.
50. Lokich JJ, Sonneborn H, Paul S, Zipoli T. Phase 1 study of continuous venous infusion of floxuridine (5-FUDR) chemotherapy. Cancer Treat Rep 1983;67:791-3.
51. von Roemeling R, Hrushesky WJM. Determination of the therapeutic index of floxuridine by its circadian infusion pattern. J Natl Cancer Inst 1990;82:386-93.
52. Hrushesky WJM, von Roemeling R, Fraley EE, Rabatin JT. Circadian-based infusional chrono-chemotherapy controls progressive metastatic RCC. Semin Surg Oncol 1988;4:110-5.
53. von Roemeling R, Hrushesky WJM. Orcadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol 1989;7:1710-9.
54. Hrushesky WJM, von Roemeling R, Lanning RM, Rabatin JT. Circadian-shaped infusions of floxuridine for progressive metastatic RCC. J Clin Oncol 1990;8:1504-13.
55. Damascelli B, Marchiano A, Spreafico C, Lutman R, Salvetti M, Bonalumi MG, et al. Orcadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. Cancer 1990;66:237-41.
56. Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Ogden S, et al. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol 1991;146:709-13.
57. Sampaio C, Olencki T, Murthy G, Budd GT, Mclain D, Lorenzi V, et al. Phase II trial of circadian infusion of the antimetabolite floxuridine in patients with metastatic RCC. J Inf Chemother 1994;4:100-3.
58. Kjaer M. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma. Cancer Treat Rev 1988;15:195-209.
59. Dorr RT. Interferon-alfa in malignant and viral diseases: a review. Drugs 1993;45:177-211.
60. Choudhury M, Efros M, Mittelman A. Interferons and interleukins in metastatic RCC. Urology 1993;41:67-72.
61. Czarniecki CW, Fennie CW, Powers DB, Estell DA. Synergystic antiviral and antiproliferative activities of E coli derived human alfa, beta, and gamma interferons. J Virol 1984;49:490-6.
62. Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP. Antiproliferative and antitumor effect of alfa-interferon in RCC: correlation to the expression of a kidney-associated differentiation glycoprotein. Cancer Res 1990;50:4190-4.
63. Quesada JR, Swanson DA, Trindale A, Gutterman JU. Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 1983;43:940-7.
64. deKernion JB, Sarna G, Figlin R, Lindner A, Smith RB. The treatment of RCC with human leukocyte alfa-interferon. J Urol 1983;130:1063-6.
65. Muss HB. The use of interferon in RCC. Eur J Cancer 1991; 27(Suppl 4):S84-7.
66. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU. Antitumor activity of recombinant-derived interferon alpha in metastatic RCC. J Clin Oncol 1985;3:1522-8.
67. Tsavaris N, Mylonakis N, Bacoyiannis Ch, Tsoutsos H, Karabelis A, Kosmidis P. Treatment of RCC with escalating doses of alpha-interferon. Chemotherapy 1993;39:361-6.
68. Kosmidis PA, Baxevanis CN, Tsavaris N, Papanastasiou M, Anastasopoulos E, Bacoyiannis C, et al. The prognostic significance of immune changes in patients with RCC treated with interferon-alfa-2b. J Clin Oncol 1992;10:1153-7.
69. Marshall ME, Simpson W, Butler K, Fried A, Fer M. Treatment of RCC with daily low-dose alfa-interferon. J Biol Response Mod 1989;8:453-61.
70. Bono AV, Reali L, Benvenuti C, Rigatti P, Gibba A, Cosciani-Cunico S, et al. Recombinant alfa interferon in metastatic RCC. Urology 1991;38:60-3.
71. Muss HB, Costanzi JI, Leavitt R, Williams RD, Kempf RA, Pollard R, et al. Recombinant alfa interferon in RCC: a randomized trial of two routes of administration. J Clin Oncol 1987;5:286-91.
72. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced RCC: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993;11:1368-75.
73. Umeda T, Niijima T. Phase II study of alpha-interferon in RCC: summary of three collaborative trials. Cancer 1986; 58:1231-5.
74. Schnall SF, Davis C, Ziyadeh T, Kirkwood JM, Pasquale D, Bobrow S, et al. Treatment of metastatic renal cell carcinoma (RCC) with intramuscular (IM) recombinant interferon alpha A (IFN, Hoffman-LaRoche) [abstract]. Proc Am Soc Clin Oncol 1986;5:227.
75. Creagan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA, et al. A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal cell adenocarcinoma. J Clin Oncol 1991;9:2104-9.
76. Figlin RA, Abi-Aad AS, Belldegrun A, deKernion JB. The role of interferon and interleukin-2 in the immunotherapeutic approach to RCC. Semin Oncol 1991;18(5 Suppl 7):102-7.
77. Horoszewicz JS, Murphy GP. An assessment of the current use of human interferons in therapy of urological cancers. J Urol 1989;142:1173-80.
78. Rinehart J, Malspeis L, Young D, Neidhart JA. Phase I/II trial of human recombinant beta-interferon serine in patients with RCC. Cancer Res 1986;46:5364-7.
79. Kish J, Ensley J, Al-Sarraf M, Ratanatharathorn V, Karanes C, Galicky P. Activity of serine inhibited recombinant DNA beta interferon (IFN beta) in patients with metastatic and recurrent renal cell cancer [abstract]. Proc Am Assoc Cancer Res 1986;27:184.
80. Kinney P, Triozzi P, Young D, Drago J, Behrens B, Wise H, et al. Phase II trial of interferon-beta-serine in metastatic RCC. J Clin Oncol 1990;8:881-5.
81. Aulitzky WE, Aulitzky W, Ellerhorst J, Logothetis C, Somahr A, Stöckle M, et al. Intermittent low-dose IFN gamma treatment for metastatic renal cell carcinoma: analysis of factors predicting clinical response and long-term survival. Onkologie 1995;18:339-45.
82. Heider A, Moritz T, Elmaagli A, Kreß M, Seeber S, Niederele N. Interferon (IFN) gamma in the treatment of metastatic RCC [abstract]. Proc Am Soc Clin Oncol 1993;12:239.
83. Lümmen G, Goepel M, Mollhoff S, Hinke A, Otto T, Rübben H. Phase II study of interferon-γ versus interleukin-2 and interferon-α2b in metastatic RCC. J Urol 1996;155:455-8.
84. Kasakura S, Lowenstein L. A factor stimulating DNA synthesis derived from the medium of leucocyte cultures. Nature 1965;206:794-5.
85. Morgan DA, Ruscetti FW, Gallo RG. Selective in vitro growth of T-lymphocytes from normal bone marrows. Science 1976;193:1007-8.
86. Gillis S, Union NA, Baker PE, Smith KA. The in vitro generation and sustained culture of nude mouse cytolytic T-lymphocytes. J Exp Med 1979;149:1460-76.
87. Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983;302:305-10.
88. Bazan JF. Unraveling the structure of IL-2. Science 1992; 257:410-3.
89. Kroemer G, Andreu JL, Gonzalo JA, Gutierrez-Ramos JC, Martinez C. Interleukin-2, autotolerance and autoimmunity. Adv Immunol 1991;50:147-235.
90. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci U S A 1990;87:5031-5.
91. Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N, et al. Cloning of the γ chain of the human IL-2 receptor. Science 1992;257:379-82.
92. Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986;58:2764-72.
93. Gearing AJH, Thorpe R. The international standard for human interleukin-2: calibration by international collaborative study. J Immunol Methods 1988;114:3-9.
94. Vlasveld LT, Beijnen JH, Sein JJ, Rankin EM, Melief CJ, Hekman A. Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteins. Eur J Cancer 1993;29A:1977-9.
95. Konrad MW, Hemstreet G, Hersh EM, Mansell PW, Mertelsmann R, Kolitz JE, et al. Pharmacokinetics of recombinant interleukin-2 in humans. Cancer Res 1990;50:2009-17.
96. Kolitz JE, Weite K, Wong GY, Holloway K, Merluzzi VJ, Engert A, et al. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin-2. J Biol Response Mod 1987;6:412-29.
97. Gambacorti-Passerini C, Radrizzani M, Marolda R, Belli F, Sciorelli G, Galazka AR, et al. In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin-2. Int J Cancer 1988;41:700-6.
98. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988;6:669-78.
99. Caligiuri M, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin-2. J Clin Invest 1993;91:123-32.
100. Cotran RS, Pober JS, Gimbrone MA Jr., Springer TA, Wiebke EA, Gaspari AA, et al. Endothelial activation during interleukin-2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 1988;140:1883-8.
101. Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 1988;48:5864-7.
102. Kasid A, Director EP, Rosenberg SA. Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration of cancer patients. J Immunol 1989;143:736-9.
103. Wiebke EA, Rosenberg SA, Lotze MT. Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J Clin Oncol 1988; 6:1440-9.
104. Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 1990;322:959-65.
105. Parkinson DR. Interleukin-2 in cancer therapy. Semin Oncol 1988;15:10-26.
106. Nora R, Abrams J, Tait N, Hiponia DJ, Silverman HJ. Myocardial toxic effects during recombinant interleukin-2 therapy. J Natl Cancer Inst 1989;81:59-63.
107. Osanto S, Cluitmans FHM, Franks CR, Bosker HA, Cleton FJ. Myocardial injury after interleukin-2 therapy. Lancet 1988;2:48-9.
108. Gaynor ER, Vitek L, Sticklin L, Creekmore SP, Ferraro ME, Thomas JX Jr., et al. The hemodynamic effects of treatment with interleukin-2 and lymphokine activated killer cells. Ann Intern Med 1988;109:953-8.
109. Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenburg SA. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 1987;69:1654-60.
110. Snydman DR, Sullivan B, Gill M, Gould JA, Parkinson DR, Atkins MB. Nosocomial sepsis associated with interleukin-2. Ann Intern Med 1990;112:102-7.
111. Post A, Falk GW, Bukowski RM. Acute colonie pseudo-obstruction associated with interleukin-2 therapy. Am J Gastroenterol 1991;86:1539-41.
112. Schwartzentruber D, Lotze MT, Rosenberg SA. Colonic perforation. An unusual complication of therapy with high-dose interleukin-2. Cancer 1988;62:2350-3.
113. Rahman R, Bernstein Z, Vaikus L, Penetrante R, Arbuck S, Kopec I, et al. Unusual gastrointestinal complications of interleukin-2 therapy. J Immunother 1991;10:221-5.
114. Fisher B, Keenan AM, Garra BS, Steinberg SM, White DE, DiBisceglie AM, et al. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol 1989;7:1852-62.
115. Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp A, Lotze MT, et al. The neuropsychiatrie effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987;107:293-300.
116. Caraceni A, Martini C, Belli F, Mascheroni L, Rivoltini L, Arienti F. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. Eur J Cancer 1993;29A:1266-9.
117. Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984;252:938-41.
118. Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI. Dermatologic changes associated with interleukin-2 administration. JAMA 1987;258:1624-9.
119. Lee RE, Gaspari AA, Lotze MT, Chang AE, Rosenberg SA. Interleukin-2 and psoriasis. Arch Dermatol 1988;124:1811-5.
120. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988;318:1557-63.
121. Zukiwski AA, David CL, Coan J, Wallace S, Gutterman JU, Mavligit GM. Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration. Cancer 1990;65:1521-4.
122. Heywood GR, Rosenberg SA, Weber JS. Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin-2. J Natl Cancer Inst 1995;87:915-22.
123. Buter J, Sleijfer DT, van der Graaf WTA, deVries EGE, Willemse PHB, Mulder NH. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol 1993;20:16-21.
124. Papa MZ, Vetto JT, Ettinghausen SE, Mule JJ, Rosenberg SA. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin-2 in mice. Cancer Res 1986;46:5618-23.
125. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP 3rd, Larrick J, et al. Cellular and molecular regulation of tumor necrosis factor-alfa production by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230-6.
126. DuBois JS, Trehu E, Mier JW, Shapiro L, Epstein M, Klempner M, et al. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 1997;15:1052-62.
127. Thompson J, Nemunaitis J, Vogelzang NJ, Fefer A, Jain V, Lestingi T, et al. Phase I trial of CT1501R in cancer patients receiving high-dose interleukin-2 (IL-2) [abstract]. Proc Am Soc Clin Oncol 1994;13:299.
128. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990;87:3629-32.
129. Package Insert for Proleukin® (aldesleukin for injection). Emeryville, CA: Chiron Therapeutics, 1992.
130. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic RCC who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
131. Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993;11:661-70.
132. Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic RCC: an interim report. J Clin Oncol 1994;12:1572-6.
133. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-13.
134. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-32.
135. Taneja SS, Pierce W, Figlin R, Belldegrun A. Immunotherapy for RCC: the era of interleukin-2 based treatment. Urology 1995;45:911-24.
136. Bukowski RM, Goodman P, Crawford ED, Sergi JS, Redman BG, Whitehead RP. Phase II trial of high-dose intermittent interleukin-2 in metastatic RCC: a Southwest Oncology Group study. J Natl Cancer Inst 1990;82:143-6.
137. Abrams JS, Raymer AA, Wiernik PH, Parkinson DR, Eisenberger M, Aronson FR, et al. High dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma. J Natl Cancer Inst 1990;82:1202-6.
138. Philip T, Negrier S, Lasset C, Coronel B, Bref M, Blay JY, et al. Patients with metastatic RCC candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients. Br J Cancer 1993;68:1036-42.
139. Palmer PA, Atzpodien J, Philip T, Negrier S, Kirchner H, von der Maase H, et al. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alfa in patients with advanced RCC. Cancer Biother 1993;8:123-36.
140. Whitehead RP, Wolf MK, Solanki DL, Hemstreet GP 3rd, Benedetto P, Richman SP, et al. A phase II trial of continuous infusion recombinant interleukin-2 in patients with advanced RCC: a Southwest Oncology Group study. J Immunother 1995;18:104-14.
141. Escudier B, Farace F, Theodore C, Angevin E, Court B, Covanet D, et al. Traitment du cancer du rein metastatique avec un nouveau schema d'interleukine-2: experience de l'institut Gustave-Roussy. Bull Cancer (Paris) 1995;82:296-302.
142. Lopez M, Carpano S, Cancrini A, Marcellini M, Del Medico P, Rinaldi M, et al. Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced RCC. Ann Oncol 1993;4:689-91.
143. Escudier B, Ravaud A, Fabbro M, Douillard JY, Negrier S, Chevreau C, et al. High-dose interleukin-2 two days a week for metastatic RCC: a FNCLCC multicenter study. J Immunother 1994;16:306-12.
144. von der Maase H, Geertsen P, Thatcher N, Jasmin D, Mercatello A, Fossa SD, et al. Recombinant interleukin-2 in metastatic RCC: a European multicentre phase II study. Eur J Cancer 1991;27:1583-9.
145. Koretz MJ, Lawson DH, York RM, Graham SD, Murray DR, Gillespie TM, et al. Randomized study of interleukin-2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch Surg 1991;126:898-903.
146. Geertsen PF, Hermann GG, von der Maase H, Steven K. Treatment of metastatic RCC by intermittent continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study. J Clin Oncol 1992;10:753-9.
147. Stoter G, Fossa SD, Rugarli C, Symann M, Jasmin C, Israel L, et al. Metastatic renal cell cancer treated with low-dose interleukin-2. A phase II multicenter study. Cancer Treat Rev 1989;16(Suppl A):111-3.
148. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced RCC. Cancer 1995; 76:824-32.
149. Negrier S, Escudier B, Lasset C, Savary J, Douillard JY, Chevreau C, et al. The FNCLCC Crecy trial: interleukin 2 (IL2) + interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC) [abstract]. Proc Am Soc Clin Oncol 1996;15:248.
150. Schomburg A, Kirchner H, Lopez-Hänninen E, Rudolph P, Korfer A, Fenner M, et al. Hepatic & serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Am J Clin Oncol 1994;17:199-209.
151. Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Archili C, et al. Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 1992;28:92-6.
152. Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Andres M, et al. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic RCC. Oncology 1994;51:59-62.
153. Lopez Hänninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996;155:19-25.
154. Casamassima A, Guida M, Latorre A, Abbate I, Triantafillou V, Musci M, et al. Effects of subcutaneous recombinant IL-2 on humoral immunity in advanced cancer patients. Intl J Oncol 1993;3:171-6.
155. deLena M, Guida M, Casamassima A, Addabbo L, Abbate I, Correale M, et al. Subcutaneous IL-2 in advanced melanoma and kidney carcinoma. Intl Oncol 1992;1:181-9.
156. Whitehead RP, Ward D, Hemingway L, Hemstreet GP 3rd, Bradley E, Konrad M. Subcutaneous recombinant interleukin-2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res 1990;50:6708-15.
157. Marumo K, Ueno M, Maraki J, Tachibana M, Deguchi N, Baba S, et al. Antitumor effects of interleukin-2 against RCC: basic study and clinical application. Urol Int 1991;47(Suppl 1):132-7.
158. Lissoni P, Barni S, Ardizzoia A, Andres M, Scardino E, Cardellini P, et al. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha first line therapy for metastatic RCC. Tumori 1993;79:397-400.
159. Jones M, Philip T, Palmer P, von der Maase H, Vinke J, Elson P, et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 1993;8:275-88.
160. Sherry RM, Rosenberg SA, Yang JC. Relapse after response to interleukin-2-based immunotherapy: patterns of progression and response to retreatment. J Immunother 1991;10: 371-5.
161. Chikkala NF, Lewis I, Ulchaker J, Stanley J, Tubbs R, Finke JH. Interactive effects of α-interferon A/D and interleukin-2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level. Cancer Res 1990;50:1176-82.
162. Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, et al. Daily alternating administration of high-dose alfa-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. Cancer 1993; 72:1733-42.
163. Spencer WF, Linehan WM, Walther MM, Haas GP, Lotze MT, Topalian SL, et al. Immunotherapy with interleukin-2 and α-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J Urol 1992; 147:24-30.
164. Budd GT, Murthy S, Finke J, Sergi J, Gibson V, Medendorp S, et al. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy. J Clin Oncol 1992;10:804-9.
165. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, et al. Combination therapy with interleukin-2 and alfa-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
166. Sznol M, Mier JW, Sparano J, Gaynor ER, Weiss GR, Margolin KA, et al. A phase I study of high-dose interleukin-2 in combination with interferon-α2b. J Biol Response Mod 1990; 9:529-37.
167. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2a: an active outpatient regimen in metastatic RCC. J Clin Oncol 1992; 10:414-21.
168. Besana C, Borri A, Bucci E, Citterio G, DiLucca G, Fords C, et al. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous α-Interferon. Eur J Cancer 1994;9:1292-8.
169. Figlin R, Citron M, Whitehead R, deKernion J, Desner M, Smith A, et al. Low dose continuous infusion recombinant human interleukin-2 (rIL-2) and Roferon-A: an active outpatient regimen for metastatic RCC [abstract]. Proc Am Soc Clin Oncol 1990;9:142.
170. Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer [abstract]. Cancer 1993;71:2358-70.
171. Bukowski RM, McLain D, Olencki T, Budd GT, Murthy SA. Interleukin-2: use in solid tumors. Stem Cells (Dayt) 1993; 11:26-32.
172. Fossa SD, Aune H, Baggerud E, Granerud T, Heilo A, Theodorsen L. Continuous intravenous interleukin-2 infusion and subcutaneous interferon-α in metastatic RCC. Eur J Cancer 1993;29A:1313-5.
173. Raymond E, Boaziz C, Komarover H, Breau JL, Moliard M, Morere JF, et al. Cancer du rein: variations des populations lymphocytaires sanguines sous traitement par interferon alfa-2b et interleukine-2r. Bull Cancer (Paris) 1993;80:299-309.
174. Lipton A, Harvey H, Givant E, Hopper K, Lawler J, Matthews Y, et al. Interleukin-2 and interferon-α-2a outpatient therapy for metastatic RCC. J Immunother 1993;13:122-9.
175. Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, et al. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced RCC. J Clin Oncol 1992; 10:1124-30.
176. Boaziz C, Breau JL, Morere JF, Raymond E, Moliard M, Israel L. Interferon and interleukin-2 in metastic cancer of the kidney: apropos of 18 cases. Ann Urol (Paris) 1991;25:163-7.
177. Wersall JP, Masucci G, Hjelm AL, Ragnhammar P, Fagerberg J, Frodin E, et al. Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma. Med Oncol Tumor Pharmacother 1993; 10:103-11.
178. Morant R, Richner J, Aapro M, Palmer PA, Senn HJ. Treatment of patients with metastatic RCC with subcutaneous recombinant interferon-alfa 2b and continuous infusion of recombinant interleukin-2: a phase II study. Onkologie 1994; 17:254-60.
179. Schiller JH, Hank J, Storer B, Borchert AA, Moore KH, Albertini M, et al. A direct comparison of immunological & clinical effects of interleukin-2 with and without interferon-α in humans. Cancer Res 1993;53:1286-92.
180. Mittelman A, Puccio C, Ahmed T, Zeffren J, Choudhury A, Arlin Z. A phase
181. Hirsh M, Lipton A, Harvey H, Givant E, Hopper K, Jones G, et al. Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy. J CHn Oncol 1990;8:1657-63.
182. Atzpodien J, Poliwoda H, Kirchner H. Alfa-interferon and interleukin-2 in RCC: studies in nonhospitalized patients. Semin Oncol 1991;18(5 Suppl 7):108-12.
183. Thiounn N, Mathiot C, Dorval T, Flam TA, Tartour E, Mosseri V, et al. Lack of efficacy of low dose subcutaneous recombinant interleukin-2 and interferon-a in the treatment of metastatic RCC. Br J Urol 1995;75:586-9.
184. Atzpodien J, Lopez Hänninen E, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic RCC. J Clin Oncol 1995;13:497-501.
185. Canobbio L, Rubagotti A, Miglietta L, Cannata D, Curotto A, Amoroso D, et al. Prognostic factors for survival in patients with advanced RCC treated with interleukin-2 and interferon-α. J Cancer Res Clin Oncol 1995;121:753-6.
186. Schneekloth C, Körfer A, Hadam M, Lopez Hanninen E, Menzel T, Schomberg A, et al. Low-dose interleukin-2 in combination with interferon-α effectively modulates biological response in vivo. Acta Haematol 1993;89:13-21.
187. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993;11:1809-16.
188. Funke I, Späth-Schwalbe E, Stohlmann G, Prümmer O, Gallati H, Schrezanmeier H, et al. Subcutaneous IL-2 and low-dose IFN-α2a in the treatment of unselected patients with advanced renal cell cancer. Onkologie 1994;17:263-9.
189. Vuoristo M, Jantumen I, Pyrhonen S, Muhonen T, Kellokumpu-Lehtinen P. A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-α in the treatment of advanced RCC or melanoma. Eur J Cancer 1994;30A:530-2.
190. Ratain MJ, Priest ER, Janisch L, Vogelzang J. A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. Cancer 1993;71:2371-6.
191. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic RCC. Cancer Res 1988;48:7310-3.
192. Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, et al. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with RCC. J Biol Response Mod 1990;9:167-77.
193. Pichert G, Jost LM, Fierz W, Stahel RA. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced RCC and melanoma. Br J Cancer 1991;63:287-92.
194. Atzpodien J, Kirchner H, Körfer A, Hadam M, Schomburg A, Menzel T, et al. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon α-2. Tumour Biol 1993;14:354-9.
195. Motzer RJ, Bander NH, Nanus DM. Medical progress: renal-cell carcinoma. N Engl J Med 1996;335:865-76.
196. Houghton JA, Morton CL, Adkins DA, Rahman A. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-α2a in colon carcinoma cells. Cancer Res 1993;53: 4243-50.
197. Danhauser LL, Freimann JH Jr., Gilchrist TL, Gutterman JU, Hunter CY, Yeomans AC, et al. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 1993;11:751-61.
198. Murphy BR, Rynard SM, Einhorn LH, Loehrer PJ. A phase II trial of interferon alpha-2A plus fluorouracil in advanced RCC. A Hoosier Oncology Group study. Invest New Drugs 1992;10:225-30.
199. Hoffmockel G, Langer W, Theiss M, Gruss A, Frohmüller HG. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-a and 5-fluorouracil. J Urol 1996;156:18-21.
200. Dutcher J, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, et al. 5FU + subcutaneous (se) interleukin-2 (IL2) plus sc Intron (IFN) in metastatic renal cell cancer (RCC) patients (PTS). A CWG study [abstract]. Proc Am Soc Clin Oncol 1996;15:272.
201. Sella A, Zukiwski A, Robinson E, Kilbourn R, Ellerhorst J, Amato R, et al. Interleukin-2 (IL-2) with interferon-α (IFN-α) and 5-fluorouracil (5-FU) in patients (PTS) with metastatic renal cell cancer (RCC) [abstract]. Proc Am Soc Clin Oncol 1994;13:237.
202. Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, et al. Phase I study of interleukin-2 combined with interferon-α and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 1994;9:103-11.
203. Gitlitz BJ, Dolan N, Pierce W, deKernion J, Belldegrun A, Figlin RA. Fluoropyrimidines plus interleukin-2 and interferon-α in the treatment of metastatic renal cell carcinoma: the UCLA Kidney Cancer Program [abstract]. Proc Am Soc Clin Oncol 1996;15:248.
204. Olencki T, Bukowski RM, Budd GT, Peerebom D, McLain D, Sandstrom K, et al. Phase I/II trial of simultaneously administered rIL-2/rHuIFNα2a and 5-FU in patients (PTS) with metastatic renal cell carcinoma (RCC) [abstract]. Proc Am Soc Clin Oncol 1996;15:263.
205. Escudier B, Farace F, Angevin E, Triebel F, Antoun S, Leclercq B, et al. Combination of interleukin-2 and gamma interferon in metastatic RCC. Eur J Cancer 1993;29A:724-8.
206. Krigel RL, Padavic-Shaller KA, Rudolph AR, Konrad M, Bradley EC, Comis RL. Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon. J Clin Oncol 1990;8:460-7.
207. Linehan WM, Walther MM, Alexander RB, Rosenberg SA. Adoptive immunotherapy of RCC: studies from the Surgery Branch, National Cancer Institute. Semin Urol 1993;11:41-3.
208. Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced RCC. J Clin Oncol 1992;10:275-81.
209. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, et al. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-85.
210. Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine activated killer cells. Ann Intern Med 1988;108:518-23.
211. Schoof DD, Terashima Y, Batter S, Douville L, Richie JP, Eberlein TJ. Survival characteristics of metastatic RCC patients treated with lymphokine-activated killer cells plus interleukin-2. Urology 1993;41:534-9.
212. Hercend T, Farace F, Baume D, Charpentier F, Droz JB, Triebel F, et al. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic RCC. J Biol Response Mod 1990;9:546-55.
213. Thompson JA, Bianco JA, Benyunes MC, Neubauer MA, Slattery JT, Fefer A. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic RCC. Cancer Res 1994;54:3436-41.
214. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr OW, Thurman G, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
215. Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, et al. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992;10:960-8.
216. Pierce WC, Belldegrun A, Figlin RA. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. Semin Oncol 1995;22:74-80.
217. Bukowski RM, Sharfman W, Murthy S, Rayman P, Tubbs R, Alexander J, et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic RCC. Cancer Res 1991;51:4199-205.
218. Rosenberg SA, Speiss P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-21.
219. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [see comments]. N Engl J Med 1988;319:1676-80. Comment in: N Engl J Med 1989;320:1418-9.
220. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [see comments]. N Engl J Med 1988;319:1676-80. Comment in: N Engl J Med 1989;320:1418-9.
221. Rayman P, Finke JH, Olencki T, Lorenzi V, Tuason L, Klein E, et al. Adoptive immunotherapy utilizing IL-2 and IL-4 for expansion of tumor infiltrating by lymphocytes in renal cell carcinoma. In: Chang AE, Shu Suyu, editors. Immunotherapy of cancer with sensitized lymphocytes. Austin, Texas: R.G. Landes Company, 1994:123-31.
222. Belldegrun A, Pierce W, Kaboo R, Tso CL, Shau H, Turcillo P, et al. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma. J Urol 1993; 150:1384-90.
223. Figlin R, Belldegrun A, deKernion J. Immunotherapy of patients with metastatic RCC (RCCA) using an outpatient regimen of interleukin-2 (il-2) and interferon-alfa (IFN) administered either alone or with in vivo primed tumor infiltrating lymphocytes (pTIL): the UCLA experience [abstract]. Proc Am Soc Clin Oncol 1992;11:197.